VPS Healthcare’s Burjeel Hospital has successfully administered advanced gene replacement therapy, in an effort to save the lives of seven-month-old Emirati twins.
With the gracious support of the government and leaders of the UAE, the therapy has been carried out on the twins by the Abu Dhabi based hospital who diagnosed them with a rare and most severe form of Spinal Muscular Atrophy – Type 1 (SMA1), a highly fatal disease.
After visiting Burjeel Hospital for a neurological assessment with Consultant Pediatrician and Child Neurologist, Dr Hussein Matlik, the twin babies were diagnosed with the rare and devastating monogenetic neuromuscular disease, SMA1, which is also known as Werdnig Hoffman disease. SMA is caused by a defective or missing survival motor neuron (SMN1) gene. The genetic disorder affects nerve cells that control voluntary muscles of the body resulting in the rapid and irreversible loss of motor neurons, affecting all muscle functions, including breathing, swallowing and basic movement. It leads to progressive muscle weakness, paralysis, and when left untreated in its most severe form, death.
“The symptoms of this devastating disease start manifesting in children in the first six months of their lives and if left untreated, the disease can lead to death or the need for permanent ventilation by the age of two in more than 90% of cases. The first consultation with the babies showed that they were severely weak, had hypotonia, as well as areflexia, which is the absence of neurologic reflexes. This led us to do a genetic test, and as a result, the SMA diagnosis test came back positive for both babies,” said Dr Matlik.
He added: “We knew that we needed to act fast and Burjeel Hospital made every arrangement for the transformational treatment to be carried out as soon as possible. Based on the available data, we are confident about the success of the therapy. This is a big achievement for the hospital, and also another success story for the UAE’s healthcare ecosystem.”
Under the supervision of Dr Amro El-Saddik, VPS Healthcare Excellence Director and his team, the infants have been subjected to AVXS-101 (onasemnogene abeparvovec) gene replacement therapy. This potentially transformational therapy targets the root cause of the disease with a single dose that introduces a functional SMN1 gene to restore SMN protein expression. Available data for previous administration of the therapy is reassuring, and shows that the treatment is both effective and safe.
Parents of the twins, Rashid Al Hasani and Mona Ali said they are optimistic about the treatment. Adding: “We are incredibly grateful to Dr Matlik and the team at Burjeel Hospital for diagnosing our children so swiftly and offering this life-saving gene therapy treatment. We are feeling very positive.”
Genpharm’s CEO, Karim Smaira commented: "Genpharm and Burjeel hospital share common values in ‘Putting Patients First’. It was greatly evident through their great efforts and their thorough follow up from diagnosing this rare and devastating disease to securing promptly the required authorizations to make the treatment administration possible."
Since 2012, Burjeel Hospital has been providing world-class, specialised private healthcare to the growing Emirate of Abu Dhabi. The hospital is part of VPS Healthcare, one of the leading healthcare groups in the UAE. -- Tradearabia News Service

Copyright 2021 Al Hilal Publishing and Marketing Group Provided by SyndiGate Media Inc. (Syndigate.info).

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.